Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib vs Adalimumab in Rheumatoid Arthritis (SELECT-SWITCH)
NCT05814627Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein <= 3.2 at 12 weeks and Number of Participants with Adverse Events at 58 weeks. Started Jun 2023; status: completed.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05814627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814627.